The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
It is now recognized that target and compound identification, as well as validation, are better conducted using cells with physiologically relevant phenotypes and genotypes. This assertion has accelerated the adoption of primary cells, stem cells, or patient-specific cells in cellular research, in general; and drug discovery, in particular.
Technological improvements in three-dimensional (3D) cell culture technology, as a means to better mimic in vivo physiology, have accelerated recently—not only in the areas of cancer and neurological research, but also for the assessment of compound metabolic and toxicological liabilities. Furthermore, 3D cell culture can provide novel approaches to the scale-up and manufacture of biologically based medicines, including those used in immuno-and stem cell-based therapies.
In this presentation, the existing and future impact of 3D cell culture technology on fundamental research, and drug discovery and manufacture will be addressed, particularly in the context of using phenotypically relevant cells. Specifically, it will discuss the potential for spheroids, organoids, scaffolds, and hydrogels in cellular research and compound identification, screening, and development.
Future directions will also be covered, including organs-on-chips, hydrostatic flow technologies, microfluidics, and 3D bioprinting. Some of these approaches will allow for real-time observation of cellular responsiveness to novel compounds and drugs … boldly taking the researcher into a fourth dimension of 3D cell culture!
The quality control (QC) of radiation-therapy (RT) treatment units is essential to deliver safe and effective radiation-therapy treatments. The complexity of the equipment and treatment techniques demands that many different tests be performed with varying frequencies, making the management of an RT department’s QC programme a complex and time-consuming task. Many professionals such as therapists, service engineers and physicists are working in collaboration to meet the machine QC requirements.
AQUA is a departmental quality-management software that centralizes all of the machine QC activities, helping to manage the complexity of quality-assurance requirements in a radiation-therapy department. AQUA is a server-based application that can be accessed throughout a RT department using a web browser. It uses a centralized database to consolidate all QC tests, procedures and results in one location and offers a workflow manager to guide the users in their day-to-day QC tasks. QC tests in AQUA can easily be created or customized using a XML-based scripting language. Integration between AQUA and the Elekta linear accelerators and other measurement devices (such as MV flat panels, electrometers and 2D arrays) using a built-in software interface has been implemented to automate time-consuming tasks. Finally, review tools such as near-real-time dashboard, plotting tool and reports are available in AQUA to streamline machine-performance assessment.
In this presentation, we will review some of the main AQUA features such as the workflow manager, QC test scripting language, and the dashboard for performance and compliance review. We will also describe test automation for some QC tasks and review the impact on QC workflows and test frequency. We will then discuss the impact of efficient review tools on the ability to detect change in machine performance and to guide servicing decisions. Finally, we will review new features in the up-coming version of the software.
Mass spectrometry-based protein assays impart increased specificity and more rapid development times versus traditional methods, such as ELISA. Coupled with immunoaffinity enrichment, LC-MS/MS is becoming a powerful tool for the quantitation of proteins in plasma. Such methods typically rely on synthetic stable isotope labeled (SIL) peptide internal standards to correct for instrumental variability. For more accurate protein quantitation by LC-MS/MS, experimental variations throughout the entire sample preparation workflow, including protein fractionation, immunoaffinity enrichment, and enzymatic digestion, must be accounted for. An ideal way of improving assay reproducibility is to add a full-length stable isotope labeled recombinant protein, that is equivalent to the native target protein, to the sample at the initial stage of the assay workflow. We have developed a set of stable-isotope-labeled monoclonal antibodies expressed in CHO cells as well as SIL versions of several clinically-relevant human proteins expressed in E. coli, such as IGF1, and in mammalian HEK293 cells, such as Thyroglobulin (manufactured as a Certified Reference Material). We will present data to demonstrate that the use of full-length SIL proteins and antibodies as internal standards allows for more accurate and rapid quantitation of biotherapeutic antibodies and clinically-relevant human protein biomarkers in plasma by LC-MS/MS.
Pharmaceutical marketers are increasingly native multichannel practitioners, but building an effective and efficient campaign is challenging.
This is also because the digital landscape, and the number of options available is still rapidly evolving.
What are the best ways to choose the right channels and the right content? And how can you plan to optimize operations further by cutting down on costs and approval times?
This webinar brings together experts in digital marketing with case studies from a leading pharmaceutical company to keep you up to date with the latest technology and trends and provide practical advice on how to maximize your impact.
Within one hour, you’ll discover how to optimize and streamline all content-related processes within a single platform: starting with concept development and ending with the final launch. What is more, you will find out how to reuse and repurpose your ready-made content cost-effectively, as well as save time while adapting and updating content through its whole lifecycle.
•How to develop best practice and a winning multichannel strategy
•Making sure your content supports face-to-face interactions
•Transforming the commercial teams to deliver successful digital and multichannel projects
•How to innovate in multichannel, and the potential of future integration solutions
This practical webinar will demystify much of the process of writing and submitting your research and the peer review process. Learn from and interact with top editors in the Chemical Engineering research community to help you successfully publish your next article.
Dr. Michael P. Harold
Dr. Michael P. Harold is the M.D. Anderson Professor and Department Chair of Chemical and Biomolecular Engineering at the University of Houston. With expertise in reaction engineering and catalysis, Dr Harold is the author of more than 140 peer-reviewed papers and has given over 260 presentations and invited lectures. He is the founder and principal investigator of the University of Houston’s Texas Center for Clean Engines, Emissions & Fuels (TxCEF), established in 2003. Dr Harold was appointed Editor-in-Chief of the AIChE Journal in late 2011, the 7th in the Journal’s 57-year history. His honors include the 2013 Ester Farfel Award at the University of Houston (highest honor bestowed on a faculty member) and he American Chemical Society’s Fuel Division Richard A. Glenn Award.
Dr. João B.P. Soares
João Soares is a Professor in the Department of Chemical and Materials Engineering at the University of Alberta (Edmonton, AB, Canada). He holds a Campus Alberta Innovates Program (CAIP) Chair in Interfacial Polymer Engineering for Oil Sands Processing, and a Canada Research Chair (Tier I) in Advanced Polymer Reaction Engineering.
Professor Soares is the Editor-in-Chief for The Canadian Journal of Chemical Engineering, and a member of the Executive Advisory Board of Wiley-VCH Macromolecular journals.
Professor Soares is a Fellow of the Chemical Institute of Canada, a Fellow of the Canadian Academy of Engineering, and a Professional Engineer in the Provinces of Ontario and Alberta.
Wiley y la Dirección General de Bibliotecas y Publicaciones - Biblioteca Central de la UNMSM tienen el agrado de invitarles a nuestro Taller de Autor en línea para investigadores. Los temas a tratar incluyen: Cómo elegir el journal correcto, Cómo proceder con las revisiones, todo sobre “Peer Review”, y mucho más.
Todos estos temas de suma relevancia para incrementar las posibilidades de publicar su artículo.
The advent of MRI-guided radiation therapy has introduced MRI’s powerful soft- tissue contrast into the treatment room, offering strong potential for improved targeting in many disease sites. In February 2017, ViewRay’s MRIdian linear accelerator (linac) received FDA clearance and the first patient treatment using MRIdian® Linac was conducted at Henry Ford Cancer Institute in July 2017. In this webinar, two key physicists involved in this project, Anthony Doemer, M.S., and Carri Glide-Hurst, Ph.D., will present their commissioning and clinical experience. Initial site planning, shielding, and MR safety considerations will be shared. The design aspects and functionality of the double-focused MLC, mechanical, and radiation characterization and validation will be presented. Commissioning of the MRI system, including novel aspects such as distortion assessment and field homogeneity in the presence of the linear accelerator will be highlighted. First clinical images and treatment plans will be shared to highlight the first months of clinical operation.
ADCs are complex compounds resulting from the coupling of cytotoxic small molecules to a monoclonal antibody. Their characterization as well as their bioanalysis (quantification in biological fluids) remains challenging. Mass spectrometry at different levels (intact, middle, peptide) can be a valuable tool, and can now be used in a regulated environment thanks to advances in both hardware and software.
Join us for the first webinar in the Wiley Learn to Publish series and learn all you need to know to publish your next article with confidence. Learn from and interact with top editors in the research community during the live Q&A sessions and connect with other researchers in the BrightTalk community.
Register for the first FREE webinar now and you’ll receive guidance from expert editors on:
•Selecting the RIGHT journal – How to choose the best outlet for your research
•Preparing your article – How to follow author guidelines
•Creating a title and abstract- How to communicate your research effectively
Future webinars will include 'Peer Review and Publishing Ethics- the dos and don'ts' and 'Sharing and Promoting your Research- SEO and Altmetrics'.
Attend all three webinars to receive your free ‘Get Published’ eBook and course completion certificate.
Watch this on-demand webinar with DocuSign and Xconomy to learn about the latest research on alternative financial models for drug development. You will also learn how you can speed up contract and approval cycles by using an eSignature solution for everything ranging from clinical trials to distribution when bringing new products to market.
Wiley invites early career researchers to the second annual Wiley Humanities Festival!
Register today for Humanities Publishing 101 and join Wiley for a FREE webinar panel discussion from notable journal editors and scholars based around your needs as a researcher. You’ll hear advice on the best practices to getting published and discover the unspoken rules of publishing research in the Humanities.
Ann E. Larabee, Editor, The Journal of Popular Culture
Professor Michigan State University
20th-Century and Contemporary Literature
Dr. Willem B. Drees
Editor, Zygon: Journal of Religion & Science
Professor & Dean, Tilburg School of Humanities
Udo Schuklenk, PhD
Professor of Philosophy and Ontario Research Chair in Bioethics
Joint Editor-in-Chief Bioethics & Developing World Bioethics
Department of Philosophy
Associate Editorial Director, Social Sciences & Humanities,Wiley
Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare.
But how can healthcare systems make this transition – and how do pharmaceutical companies play a role in this, while also growing their market?
A forthcoming webinar hosted by pharmaphorum with sponsor PHOENIX group looks at how harnessing the data and expertise of pharmacies, and via greater engagement with patients, consumers and shoppers can meet this emerging need.
•Industry: how can pharma switch from treating a disease to earlier health management?
The role of preventative medicine, vaccines and early diagnosis explored
•The role of community pharmacies in prevention and health – increasing screening and diagnosis rates and facilitating appropriate medication
•How point of sale information in pharmacies can help generate a picture of patient groups and individuals. How loyalty card schemes support OTC and consumer spending patterns, which illuminate health needs, prescription patterns and purchasing behaviour
Want to learn more about the Pentaho Trial? Then attend this recorded webcast that focuses on big data and data integration best practices as well as how to get the most out of your Pentaho 30-day trial.
Other topics include:
* A review the components that are part of your trial and best approach to get started
*A discussion on the best way to connect to your data and manage your analytical pipeline
* A showcase our library of videos, tutorials and documentation for a smooth trial
* Highlights of proven best practices to make the most of your 30-day download
Digital health brings a diverse range of growth opportunities for vendors across the value chain. As the space evolves we have experienced a multitude of stepwise successes and stellar failures, yet funding continues to flood the sector. Major moves continue to come into the industry from the broader vendor environment, underlining the importance of health in everyone’s lives and progressively in strategic interests of the C-Suite across the ecosystem. Join Frost & Sullivan in this webinar update showcasing different facets of the market, and learn why there’s something for everyone in digital health.
Historically, quality of biological products has been ensured through testing representative samples. Shift in quality paradigm started with implementation of Good Manufacturing Practice (GMP) regulations with current focus on building quality during manufacture. Inherent variability and complexity of biological products pose challenges in implementing Quality by design (QbD) concept. This presentation discusses ways to build quality during manufacture of biological products.
Innovation in chemistry is required in all sectors of industry, whether it be in pharmaceuticals, material science, or indeed any other branch of science. These innovations are the foundation of our modern society and lead the way for businesses to progress - and help the world to progress.
Chemical by PatSnap seamlessly links chemical structure searches to intellectual property data, enabling you to effortlessly discover chemical structures linked to the most relevant of patents, no matter how they’re described or written.
In this webinar, we’ll be joined by Chemist and IP expert Andy Lai as he demonstrates how you can validate your target chemicals performance against 114 million structures, from over 100 patent jurisdictions.
Some other topics that will be discussed include:
- How to utilize the similar search function to discover structures very close to yours
- How the Chemscape can highlight opportunities for licensing and collaboration
- Discover what the good chemical performance indicators look like
PlumX Metrics will soon become the primary source of article-level metrics on Scopus. As Plum Analytics’ comprehensive, item-level Metrics, PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters and many more) in the online environment.
Next-generation sequencing (NGS) has emerged as a key technology to deliver the next level of healthcare solutions. While the $1,000 genome was achieved in 2015, Frost & Sullivan predicts the $100 genome to be possible by 2024. The significant dip in cost of extracting genetic data has led to the creation of massive genomic data volumes that are expected to be some of the largest data sets globally by 2025, exceeding data generated by YouTube and Twitter.
During this webinar you will receive tips and tricks on:
•Understanding the principles of rotary evaporation
•Learning how to maximize output
•Finding out how to minimize contamination
•Handling different sample sizes and types
Hospital information technology (Hospital IT) spending in Asia-Pacific (APAC) will grow at a compound annual growth rate of 9.7% between 2016 and 2021 to reach an estimated end-stage market size of more than $15 billion. Key growth opportunities in the region include solutions for Healthcare Data Continuity, Patient Engagement & Experience, Healthcare Cloud, Big Data & Analytics, and Healthcare Cybersecurity. However, the identification of these growth opportunities is only the first step toward succeeding as an ICT vendor in this market. The real demystification lies in understanding very specific target customer needs and then building a value proposition and business model that addresses those needs.
1. The kidney proximal tubule is the primary site of drug-induced nephrotoxicity. I will describe the development of a 3-dimensional flow-directed proximal tubule microphysiological system (MPS). The kidney MPS recapitulates the synthetic, metabolic and transport activities of kidney proximal tubule cells. This MPS is as an ideal platform for ex vivo modeling of nephrotoxicity. Towards this goal, we have evaluated nephrotoxicity in response to challenge with multiple toxicants, including the heavy metal pollutant cadmium, antisense oligonucleotides, the antibiotic polymyxin B and the Chinese herbal product aristolochic acid. We believe that MPS technologies will have major impacts on predictive toxicity testing and human risk assessment. Animal and in vitro systems do not always faithfully recapitulate drug and xenobiotic responses in the clinic or occupational/environmental exposures, respectively. MPS technologies will refine safety assessment and reduce our need for surrogate animal testing. An ultimate goal is to create integrated human MPS organ systems that could replace animal models.
2. Nortis has developed a technology that is used to recapitulate functional units of human organs in microfluidic devices (chips). Such organ models include vasculature, kidney, and liver models for toxicology studies, blood-brain barrier models for drug transport studies, and vascularized tumor microenvironment models for drug efficacy studies.
Join us to find out about the results of the 2017 Multichannel Maturometer. The ninth version of this industry-renowned survey illuminates some of the big changes sweeping through the Pharma industry, as well as highlighting some trends which are still lagging.
Questions which will be answered include:
• Is senior leadership still on the fence for digital?
• Marketing budgets – how are they changing?
• How satisfactory are those in the industry finding digital offerings?
Scopus has recently added over 195 million more cited references dating back to 1970 to complement the database's existing records that date back 1788 and further increase the depth of content.
Added cited references mean:
•more extensive bibliometric and historic trend analysis
•more complete author profiles
•improved h-index measures for authors who began publishing prior to 1996
Learn more about the depth of Scopus content along with more insights into our content policies, selection criteria and data quality.
The biggest tech companies in the world are also the best at customizing their offerings for customers, and predicting what they want. Amazon, Google, and Netflix have been consistently using AI and predictive marketing analytics to first achieve and then maintain their supremacy. Their internal knowledge, matched with large quantities of structured data and a laser focus on what ‘good’ looks like, have been the drivers of their success.
However, in life-sciences marketing, reality has not caught up to the buzz of self-learning systems (AI) and predictive analytics. However, adoption is increasing (albeit slowly), and more and more leaders are excited by benefits their investments may bring.
Our 2017 Multichannel Maturometer revealed that only around half of major life-sciences companies have an integrated customer database across all channels, and digital teams are only slowly being integrated with their IT partners. And as a further challenge, only 20% are claim to be ‘very comfortable’ with measuring HCP engagement.
For companies to really embrace the future of analytics, it is crucial to move from “predictive guessing” to “predictive knowing”. A well-integrated customer database across all channels, a good understanding of what means success, large-enough datasets, ... are just some of the key components for this transition.
In this webinar, we will talk about:
• How does predictive analytics differ from prescriptive analytics?
• When can predictive analytics become relevant (and when not)?
• What are the different enablers for engaging in predictive analytics?
• A few examples to get inspired
We invite you to join Frost & Sullivan’s Transformational Healthcare team and industry experts to discuss blockchain technology with the most potential applications across the healthcare industry, including data interoperability, cybersecurity, insurance fraud management, and drug supply chain provenance. Learn how to differentiate the hype from reality and hear key strategic considerations for future success.
The recent global hacks on companies and organisations including Merck, Mondolez International, Rosneft and the NHS have demonstrated that all different types of industries are at risk when it comes to cyber attacks/hacks.
Most people think about the obvious affects such as consumer data infringement or loss of functionality but what can an attack mean for your R&D department?
Jeff Middleton, CEO of Lantium, who build bespoke cyber security solutions, will take us through the learning's of recent "Petya" and "WannaCry" attacks, as well as how we can prevent and minimise losses in such instances.
Topics covered in this webinar:
- Recent Global Attacks and learning
- How Cyber attacks affect R&D, M&A and IP
- What to consider when creating a cyber-safety strategy.
Essential viewing for anyone that runs a company where data could be at risk.
We hope you join us for this special webinar. Jeff Irelan, Director of Scientific Applications for Organovo will be our guest presenter.
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with an estimated prevalence of over 25% worldwide and is projected to become the leading indication for liver transplant by 2025. Despite decades of research focused on NAFLD, an effective treatment has yet to be approved. This is due in part to the reliance on cell culture and animal models that present challenges in translation due to limited functional longevity and species differences, respectively.
ExVive™ 3D Bioprinted Human Liver Tissue, a clinically-translatable in vitro model, is ideal for studying the effects of drugs on liver disease progression, regression, and the mechanisms involved. Here, we present results showing a nutrient overload induction of liver disease and TGFβ-induced fibrosis in ExVive™ Human Liver Tissue. A variety of disease-relevant phenotypes including steatosis, inflammation, and fibrosis can be demonstrated in the model:
•Nutrient overload leads to the accumulation of lipid droplets in hepatocytes.
•Incorporation of Kupffer cells and stimulation induces inflammatory cytokine release.
•Chronic exposure to nutrient overload leads to stellate cell activation and fibrosis.
•Chronic exposure to chemical inducers of fibrosis or TGFβ stimulation leads to stellate cell activation and fibrosis.
•A TGFβR1 kinase inhibitor effectively blocks TGFβ-induced fibrosis.
Jeff Irelan holds a Ph.D. in molecular biology from the University of Oregon. As Director of Scientific Applications, Jeff interfaces with Organovo’s customers and R&D team to implement and expand the company’s portfolio of service offerings utilizing bioprinted tissue models.
Join us for our live publishing clinic and learn all you need to know to publish your next article with confidence. Learn from and interact with top editors in the research community during the live Q&A sessions and connect with other researchers in the BrightTalk community.
Register for our FREE webinar now and you’ll receive guidance from expert editors on:
•Selecting the RIGHT journal – How to choose the best outlet for your research
•Preparing your article – How to follow author guidelines
•Peer Review/Rejection – How to address reviewer comments and prepare for resubmission
•Post publication and SEO – How to promote your work
Dr. Gert-Jan van de Geijn, renowned hematology expert, researcher and industry leader, will discuss new chronic obstructive pulmonary disease (COPD) test parameters that better discriminate between bacterial and nonbacterial acute exacerbation. Dr. van de Geijn will share how neutro/lympho ratios and basophils (measured by flow) combined with current C-reactive protein (CRP) tests enable more accurate bacterial detection in COPD patients.
After this live webinar, you will be able to:
-Assess options based on the limitations of current differentiation tests (e.g., sputum culture and CRP)
-Apply multivariate analysis results from hematology and flow cytometry technologies to increase specificity
-Combine tests to improve prediction of bacterial exacerbation in COPD patients to help reduce antibiotics resistance
A live Q&A session will follow.
P.A.C.E. credit is available for your participation.*
Gert-Jan van de Geijn, Ph.D., has nearly 20 years of experience in hematology and laboratory medicine. He is a specialist in multiple technologies related to cellular analysis, including both flow cytometry and molecular biological techniques. He has published and contributed to more than 30 research articles. Currently, Dr. van de Geijn is a research coordinator for the Department of Clinical Chemistry at Franciscus Gasthius Hospital, Rotterdam, the Netherlands.
*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
Following a decade (or more) of concerted effort by industry, regulator, and academic groups, recent technology investments are now beginning to shape how medicines are being developed and manufactured for the global marketplace. While significant focus has highlighted the emergence of continuous manufacturing processes, three additional trends have also influenced and served as underlying drivers for these technology investments. First, the emergence of scientific advances in targeted biology has created high-value personalized medicines with smaller manufacturing volumes (doses/annum). Second, new regulatory pathways, such as the FDA’s Breakthrough Therapy designation, have accelerated the development and commercialization timelines for these new medicines. Finally, manufacturing localization has extended supply chain networks to serve globally-distributed patient populations throughout the world. Together, these drivers have served to shape the future of pharmaceutical development, manufacturing, and distribution of a variety of different dosage forms. The increasing need for product development speed and commercial supply flexibility through small-footprint, modular equipment trains will be highlighted within this paper, using an immediate-release solid oral dosage form example.
Patient insights aren’t just a ‘nice to have’: they are essential to understand the space where Pharma’s drugs ‘live’.
On the 10th October, Cello Health Insight in association with PMGroup, will look at the value of three areas of patient research that provide that ‘must have’ understanding: mapping the patient pathway, patient motivation, and the dialogue between patient and HCP.
This webinar will provide an overview of recent advances in RAFT agents (900150, 900157 and 900158). New dithiocarbamate RAFT agents are extremely versatile, RAFT agents with wide-spread monomer applicability. The RAFT agents have the distinct advantage of low odour levels and in addition to this and the derived polymers do not develop odour on storage as no low molar mass thiols are generated. In most cases they are an appropriate replacement for trithiocarbonate RAFT agents. The new RAFT agents have the ability to control polymerization of both MAMs (more activated monomers) and LAMs (less activated monomers) and have been shown to be suitable for the synthesis of poly(MAM)-block-poly(LAM), specifically poly(DMA)-blockpoly(VAc).
With the Ray Optics Module, an add-on product to the COMSOL Multiphysics® software, you can use simulation to predict the paths of light rays, including diffuse and specular reflection, refraction, absorption and dispersion of polychromatic light. You can also analyse ray intensity, polarization and monochromatic aberrations.
This webinar will focus on how ray tracing can be combined with other types of physics in a model. For example, you can model the effects of thermal stress in high-powered laser focusing systems and even couple wavelength-scale modelling of antennas and semiconductor devices to ray tracing simulations on a much larger scale.
The webinar includes a live demonstration and will conclude with a Q&A session.
McCann Health partnered with McCann Truth Central, the global intelligence unit of McCann Worldgroup, to conduct vital research.
On the 19th October, McCann Health in association with PMGroup, will look at the truth they uncover about health.
‘The Truth about Doctors’ the first study in the series, aims to get to the heart of the human under the white coat to better understand what motivates doctors and how we can improve the way we communicate to them.
The in vitro micronucleus assay is one of the most widely used tests to quantify genotoxicity and cytotoxicity, especially as a screening tool in the development of chemicals and pharmaceuticals. Micronuclei (MN) are formed from whole chromosomes or chromosome fragments that lag behind during the metaphase-anaphase transition and are excluded from the main nucleus following division. MN form into small, rounded bodies surrounded by their own nuclear envelope and represent chromosomal mutations that can be used as an endpoint in genotoxicity testing. Typically performed by manual microscopy, the MN assay is laborious and can be subject to scorer bias. To overcome this, automated microscopy and conventional flow cytometry methods have been developed. However, these methods suffer from several limitations such as the requirement to create high quality slides in the case of microscopy and the lack of visual confirmation of MN in the case of flow cytometry. The ImageStream®X (ISX) imaging flow cytometer has the potential to overcome these limitations as it combines the speed, statistical robustness and rare event capture capability of conventional flow cytometry with high resolution fluorescent imagery.
In this webinar, adaptation of the in vitro MN assay to an imaging flow cytometry-based method will be described. Using the ISX Mark II imaging flow cytometer, images of micronucleated mono- and binucleated cells as well as polynucleated cells can be captured at a high flow rate and automatically identified and scored in the Image Data Exploration and Analysis Software (IDEAS®) that accompanies the ISX. A data analysis template created specifically for this application allows for the determination of both genotoxicity and cytotoxicity following treatment with known clastogens and aneugens. This work is the first demonstration of fully automated method for performing the in vitro MN assay on an imaging flow cytometry platform.
The industry is being disrupted by integration of the multi-disciplinary capabilities in biology, chemistry and computational power that companies can leverage to develop new solutions to diagnose, treat and manage chronic disease conditions, such as cancer, cardiovascular disease and diabetes. There is immense pressure on companies to build competencies in product development, manufacturing and distribution of new technology platforms such as point-of-care molecular diagnostics to capture new growth opportunities in the precision medicine market—a paradigm shift that will transform clinical practice and treatment outcomes.
Common mammalian cell lines used for biopharmaceutical production include Chinese Hamster Ovary (CHO), NS0 and Human Embryonic Kidney (HEK) cells. Each of these cell lines has been found with over 20,000 genes coded in their genome, which can result in over 10,000 proteins expressed at the same time in these cells. These proteins can be secreted from the living host cells or released to the cell culture supernatant upon lysis of the host cells during the cell culture. Biopharmaceuticals produced using these cell lines can be co-purified with a subset of the host-cell proteins (HCPs) in the cell culture supernatant.
These co-purified HCPs are considered process-related impurities for biopharmaceuticals. The HCPs can cause potential safety risks by introducing anti-HCP response in the patients. Depending on the biological functions of the residual HCPs, other potential impacts reported include lowering the biopharmaceutical protein stability and affecting the efficacy of the biopharmaceutical protein by exacerbating the symptoms.
Since the introduction of disposables and gaining popularity of Single-use Technology (SUT) for biopharmaceutical manufacturing there is nevertheless an ongoing controversial discussion on the advantages and disadvantages versus a conventional stainless steel environment.
In a “classical” facility design any validation cost effort can easily be distributed to a considerable number of production runs thus contributing only to a non-decisive amount to the overall production costs. The scale for such plant is nearly unlimited as is the scale of operation. The “flexible” approach using disposables and single-use equipment offers significant advantages regarding changeover work and time thus a high throughput of different processes will definitely take profit as any cleaning and related validation and costly analytics doesn’t apply to a larger extent.
Despite the potential benefits loudly advertised by the respective industry, these potential advantages derived from single-use equipment and disposables can be significantly diminished by lack of detailed process cost analysis, missing economic analysis and cost comparison between conventional and SU technologies as well as underestimating the cost of long term dependency on consumables. Due to missing appropriate standards, there is a widely non-compatibility between the equipment and consumables of the various suppliers, resulting in a strong dependence on the consumables of a single supplier once a single-use equipment has been purchased, curiously leaving some customers with surprise that they hardly have any room for price negotiations on the required consumables.
This paper’s focus is on the very different arguments for the application of SU equipment and consumables, including advantages and limitations of SUT, understanding improvement of process robustness, contribution to lean production as well as environmental impact of disposables.
The Cancer Vanguard is a bold initiative setup to take leadership in the delivery of the National Cancer Strategy – Achieving World-Class Cancer Outcomes published in 2015 with a key aim of designing and implementing new and increasingly patient centric models of care in Cancer that can benefit and be adopted by the wider national cancer system.
In summer 2016 the Cancer Vanguard medicines optimisation team launched the ‘Pharma Challenge’ as an opportunity for the pharma and life sciences industry to identify innovative ways in which it could work in partnership with the NHS to improve the effective use of NHS resources, enhance the NHS’ understanding of the patient experience and make medicines optimisation part of routine practice. Four projects were taken forward including a partnership between the Cancer Vanguard, QuintilesIMS, Merck and uMotif,
This unique example of partnership working across the health system is focussed on the service at large, not just the pill, and uses leading edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence based and patient centric approach to service redesign and resource optimisation.
Single-use (SU) systems are now in common use in pharmaceutical bioprocessing, as well as in other related technologies such as the manufacture of diagnostics and other biological products, and their popularity is increasing. Some types of SU systems have been in use for many decades now. The earliest SU systems being disposable filter cartridges that do not require a stainless steel (SS) filter housing. This present article seeks to focus in particular on SU bioreactors for cell culture and bacterial fermentation for the purpose of producing therapeutic proteins, monoclonal antibodies and vaccines. SU bioreactors are of particular value in early phase (Clinical Phases 1 and 2) GMP manufacturing. In some cases their use has now stretched through into commercial processing, albeit that the scale of operation is currently limited and in general the largest commercially available SU bioreactors are around 2000L working volume (WV). However, the small footprint that they require, and the reduction in investment needed for support services and utilities, means that the scale limitations can be overcome to a significant degree by having multiple SU bioreactors operating in parallel within a facility. The harvest from multiple bioreactors can be pooled for downstream processing, or each harvest can be processed as a separate batch, based upon considerations of the risks versus the economies of pooling.
David Pridham, Chief Executive Officer and Brad Sheafe, Chief Intellectual Property Officer of Dominion Harbor will be taking us through their recent acquisition of the Kodak Patent Portfolio and the steps they are taking to monetise over 4000 patents.
Unfortunately patent monetisation isn't as simple as selling or licensing, it depends heavily on the other players in the market, where the market is moving and also the litigation and future legislation when it comes to that particular technology.
This webinar will cover:
- The analytical approach (using technology to help assess the opportunity)
- The go-to-market strategy development
- How to present this strategy to potential buyers without being exposed to litigation risks
- Building global partnerships to maximise the monetisation potential of the portfolio in a heterogeneous, world-wide marketplace
- Managing prosecution, maintenance, divestiture and abandonment
As radiation-oncology clinics transition from paper to paperless environments, more documentation is being stored in computer databases. Medical-physics documentation was traditionally stored in large binders on a bookshelf and disparate Excel files on a PC hard drive. Historically this was the only option for storing the large volume of data required for regulatory compliance. In the last 5 years many vendors of radiation-oncology quality-assurance (QA) equipment have stepped up to fill this gap. Additionally, QA software is now available that combines the interfacing of hardware with QA systems. In this lecture I will cover some of the software packages available from vendors and will share the LewisGale experience in implementing one software package for integrated QA. I will conclude the lecture with some of my personal thoughts regarding suggestions for QA software vendors for the future.
Learn how to navigate the dos and don’ts of Peer Review and Publishing Ethics.
In the second of the Wiley Learn to Publish webinar series, we’ll be covering all you need to know to understand the Peer Review process and the basics of Publishing Ethics.
Hear from our expert editors on:
-The basics of the peer review process and common models
-What Reviewers are looking for
-Possible outcomes and dealing with rejection
-Your ethical responsibilities as an author
-Penalties for unethical behaviour
-Tips for navigating ethical challenges in scholarly publishing
We’ll also be answering your questions in a live Q&A.
Recently, there has been a renewed interest in the field of continuous processing. Some key factors driving this interest are – availability of better cell retention devices, improved cell lines and culture medium capable of supporting high cell densities.
These factors have contributed mainly in reducing the batch duration for making the required quantity of product, thus reducing the medium requirement and chances of batch failures significantly. With the continuous processing being considered as ‘back-in-the-game’, the question remains: Can the current perfusion technology compete or replace the conventional and widely preferred fed-batch technology?
Two cases are discussed to compare the performance features of fed-batch and perfusion processes. In both the cases, the product output from perfusion process is significantly higher (2 to 5 folds) than that from fed-batch, due to combination of factors like higher cell density, higher cell specific productivity, lower accumulation of toxic metabolites etc. These cases demonstrate the potential of perfusion process in significantly increasing the product output. However, there are certain challenges and points to be considered before a company decides to switch to a perfusion platform. Some of these are highlighted in the article.
Multi-spectral imaging flow cytometry (MIFC) is an established analytical method for cellular analysis, however has only recently been evaluated for characterization of sub-visible particles in therapeutic formulations despite numerous favorable attributes including:
• Simultaneous collection of bright-field, side-scatter, and fluorescent imagery
• Sensitive detection of particles 100 nm-100 μm
• High image quality using 20X-60X magnification objectives
• 100% sampling efficiency using hydrodynamic focusing
• Small sample volume requirement (20 μL)
• Linear concentration range up to 100 million/mL
• Wide flow cell (250 μm) minimizes clogs
Assorted case studies using MIFC for analysis of protein and vaccine formulations will be presented, with an emphasis on measurements and samples that pose challenges for current techniques- including detection of small and transparent particles, direct analysis of highly concentrated formulations, and fluorescence characterization of particle type, chemical composition, and heterogeneous interactions.
Biometrics has slowly become more and more present in our everyday lives. We no longer bat an eyelid when our phones require us to use a finger print for a payment or even when its how you get into your gym. So whats the next step?
Cubic who are the people behind the payment technology of the London Transport System has devised a system that can double the “throughput” of an entrance—from 25 people crossing a gate’s threshold per minute, to about 50 or 60. This idea could mean that we would no longer have gates at tube stations across London and instead your phone in combination with your face.
Niosha Kayhani of Cubic will be taking us through the development of this Technology and also the growing uses and industry that is Biometrics.
Maximise the impact of your published work! Find out more about sharing and promoting your research including SEO and Altmetrics.
In the third and final webinar in our Learn to Publish series, our expert editors and marketers will cover:
-What you need to do to get read, get shared and get cited
-SEO in 4 easy steps
-Title, Abstract and Keyword best practices
-Tips for building links
-Understanding Impact Factors and Altmetrics
-Tools and resources available to help you share and promote your work
We’ll also be answering your questions in a live Q&A.